Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 1742

Novel Approaches for HIV Vaccines that Elicit Neutralizing Antibodies: gp41 Locked in Fusion-intermediate Conformation

Inventors: Stephen Harrison, Bing Chen, Gary Frey

Invention Types: Therapeutics

Research Areas: Infectious Disease

Keywords: Vaccine

For More Information Contact:  Caron, Connie

 

Invention Description:

HIV/AIDS is a major global epidemic problem affecting 0.8% of worldwide population and causing ~2 million deaths each year in the entire world. As of the end of 2009, approximately 36 million persons worldwide were living with HIV/AIDS, of which 2.5 million were newly infected during the year. A successful HIV vaccine has been elusive, due to the failure to produce an immuogen that elicits the robust production of protective, neutralizing antibodies in the recipient. Drs. Chen and Harrison developed a protein structure-based paradigm to vaccine design, incorporating the understanding of the dynamic changes in protein structure that occur on viral entry into the cell.


Understanding the dynamic structure of the HIV gp41 envelop protein during viral entry, the researchers have developed gp41 protein variants that locks the protein in a conformation that is normally exposed only transiently during viral entry. Immunization with this protein elicits strong neutralizing antibody production in model animals. Further, the gp41 proteins provide a platform for screening therapeutic compounds that specifically disrupt HIV viral entry.

Patent Number: US 8,741,310

Applications:

Immunogens for an HIV vaccine that elicit robust neutralizing antibody production. |

Therapeutic screening reagents for viral entry inhibitors

Competitive Advantages:

Current AIDS treatment (HAART) is expensive and offers no cure. A preventive vaccine is greatly needed, in particular for developing countries where costly medicines are often unavailable and disease transmission continues unchecked. Currently, no one has successfully developed an HIV vaccine.

Business Opportunity:

• Exclusive or non-exclusive license to a company with existing HIV vaccine development pipeline ||
• Sponsored Research

Key Publications: A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.
Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B.
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3739-44.
PMID: 18322015

http://www.ncbi.nlm.nih.gov/pubmed/18322015

IPStatus: Patented